TapewireFind a company

person · Reporting owner

Evans David Thomas

Disclosed activity across 1 company

Tapewire entity
45995
SEC CIK
0001730451

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Cardlytics, Inc.CDLX · Entity 7603Chief Financial OfficerMay 15, 2026May 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cardlytics, Inc.

Report date May 15, 2026 · Filed May 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect317,930 Ending reported balance After 2026-05-18 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-05-15 · Purchase · Acquired 150,000 · Balance 267,930

F1: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1).

Row 2 · 2026-05-18 · Purchase · Acquired 50,000 · Balance 317,930

F2: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2).

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1).

F2: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 53,757 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · derivative · entry 9

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 53,757 shares

Expires 2026-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F7 · derivative.exercise_date: This option became exercisable with respect to one quarter (1/4) of the shares of stock subject to this option on June 15, 2017 (the "Initial Vesting Date"). The option becomes exercisable in respect of the remaining shares in thirty-six (36) equal monthly installments commencing one (1) month after the Initial Vesting Date, provided the Reporting Person continuously provides service to the Issuer through each vesting period.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 5,777 $87.68 $506,527.36
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 8

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,810

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $87.44 to $88.11, inclusive.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 9,937 $86.97 $864,220.89
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 7

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,587

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.44 to $87.43, inclusive.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 24,635 $85.80 $2,113,683.00
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 6

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,524

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.44 to $86.40, inclusive.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 30,425 $85.06 $2,587,950.50
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 5

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,159

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.44 to $85.43, inclusive.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 29,096 $83.99 $2,443,773.04
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,584

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.43 to $84.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 25,781 $30.44 $784,773.64
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 28,906 $20.00 $578,120.00
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
January 27, 2020 Filed Jan 28, 2020 22:40 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 53,757 $20.00 $1,075,140.00
Disclosure

SEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
January 15, 2020 Filed Jan 15, 2020 23:55 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,000 $85.02 $255,060.00
Disclosure

SEC source: 0001666071-20-000009 · wf-form4_157913252579532.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,236

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:02 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 600 $63.38 $38,028.00
Disclosure

SEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,236

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $63.01 to $63.52, inclusive.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:02 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,665 $62.29 $166,002.85
Disclosure

SEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,836

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.94, inclusive.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:02 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 12,115 $61.60 $746,284.00
Disclosure

SEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,501

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.99, inclusive.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:02 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 6,620 $60.36 $399,583.20
Disclosure

SEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,616

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

Read SEC document
December 16, 2019 Filed Dec 16, 2019 21:26 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,000 $57.00 $171,000.00
Disclosure

SEC source: 0001666071-19-000181 · wf-form4_157653156760441.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,236

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
December 03, 2019 Filed Dec 5, 2019 13:52 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,586 $60.00 $155,160.00
Disclosure

SEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,236

F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
December 02, 2019 Filed Dec 5, 2019 13:52 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $9.08 $0.00
Disclosure

SEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · derivative · entry 5

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires 2024-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
December 02, 2019 Filed Dec 5, 2019 13:52 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,414 $60.00 $144,840.00
Disclosure

SEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,822

F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
December 02, 2019 Filed Dec 5, 2019 13:52 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 17,000 $55.94 $950,980.00
Disclosure

SEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,236

F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
December 02, 2019 Filed Dec 5, 2019 13:52 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 22,500 $9.08 $204,300.00
Disclosure

SEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,236

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 702 shares of Common Stock acquired under the Issuer's Employee Stock Purchase Plan.

Read SEC document
November 26, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 6,540 $56.20 $367,548.00
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,034

F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of the performance stock units.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.79, inclusive.

Read SEC document
November 26, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 14,741 $55.88 $823,727.08
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,574

F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of the performance stock units.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $55.72 to $55.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes and (4) to this Form 4.

Read SEC document
November 25, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionPerformance Stock Unit · Derivative 21,875 $0.00 $0.00
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 7

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

Underlying: Common Sock · 21,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019, twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification.

F6 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019, twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification.

Read SEC document
November 25, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionPerformance Stock Unit · Derivative 21,875 $0.00 $0.00
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 6

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,625

Underlying: Common Sock · 21,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

F5 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

Read SEC document
November 25, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 GrantPerformance Stock Unit · Derivative 43,750 $0.00 $0.00
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 5

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Sock · 43,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

F5 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

Read SEC document
November 25, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 21,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,315

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 25, 2019 Filed Nov 28, 2019 00:12 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 21,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 15, 2019 Filed Nov 15, 2019 21:50 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,000 $57.12 $171,360.00
Disclosure

SEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
November 13, 2019 Filed Nov 15, 2019 21:50 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,000 $47.65 $95,300.00
Disclosure

SEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
November 13, 2019 Filed Nov 15, 2019 21:50 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 5,000 $50.00 $250,000.00
Disclosure

SEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
November 13, 2019 Filed Nov 15, 2019 21:50 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 5,000 $55.00 $275,000.00
Disclosure

SEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
November 01, 2019 Filed Nov 1, 2019 23:02 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 5,000 $41.26 $206,300.00
Disclosure

SEC source: 0001666071-19-000138 · wf-form4_157264933882343.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $41.2501 to $41.292, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
October 29, 2019 Filed Oct 30, 2019 20:15 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 3,906 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · derivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,906 shares

Expires 2026-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · derivative.exercise_date: Fully vested.

Read SEC document
October 29, 2019 Filed Oct 30, 2019 20:15 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 6,906 $40.00 $276,240.00
Disclosure

SEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
October 29, 2019 Filed Oct 30, 2019 20:15 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 3,906 $20.00 $78,120.00
Disclosure

SEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,471

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
October 15, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 31,962 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · derivative · entry 7

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,906

Underlying: Common Stock · 31,962 shares

Expires 2026-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
October 15, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,000 $37.15 $111,450.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 5

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
October 15, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 21,555 $37.50 $808,312.50
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 4

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,565

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · kind: Shares sold to satisfy exercise cost and withholding tax obligations upon the exercise of employee stock option.

Read SEC document
October 15, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 31,962 $20.00 $639,240.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 3

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
October 11, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 1,631 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · derivative · entry 6

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,868

Underlying: Common Stock · 1,631 shares

Expires 2026-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
October 11, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,100 $37.50 $41,250.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,158

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

F2 · kind: Shares sold to satisfy exercise cost and withholding tax obligations upon the exercise of employee stock option.

Read SEC document
October 11, 2019 Filed Oct 15, 2019 21:23 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 1,631 $20.00 $32,620.00
Disclosure

SEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
October 02, 2019 Filed Oct 3, 2019 21:31 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 2,000 $35.00 $70,000.00
Disclosure

SEC source: 0001666071-19-000126 · wf-form4_157013827835003.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,627

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019.

Read SEC document
August 26, 2019 Filed Aug 28, 2019 21:04 UTC Cardlytics, Inc. CDLX · Entity 7603 GrantPerformance Stock Unit · Derivative 43,750 $0.00 $0.00
Disclosure

SEC source: 0001666071-19-000107 · wf-form4_156702626589539.xml · derivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

Underlying: Common Sock · 43,750 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the first tranche of the PSU to be awarded, which shares are reflected in Column 5 above. Fifty percent (50%) of the shares subject to the first tranche of the PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 12 months after the Certification. The PSU has not yet settled.

F2 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the first tranche of the PSU to be awarded, which shares are reflected in Column 5 above. Fifty percent (50%) of the shares subject to the first tranche of the PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 12 months after the Certification. The PSU has not yet settled.

Read SEC document
August 22, 2019 Filed Aug 22, 2019 20:26 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $9.08 $0.00
Disclosure

SEC source: 0001666071-19-000097 · wf-form4_156650555845317.xml · derivative · entry 2

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Sock · 10,000 shares

Expires 2024-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

Read SEC document
August 22, 2019 Filed Aug 22, 2019 20:26 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 10,000 $9.08 $90,800.00
Disclosure

SEC source: 0001666071-19-000097 · wf-form4_156650555845317.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2019 Filed Aug 19, 2019 11:14 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,500 $33.93 $50,895.00
Disclosure

SEC source: 0001666071-19-000091 · wf-form4_156621323159130.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,627

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018.

Read SEC document
July 15, 2019 Filed Jul 15, 2019 22:04 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,500 $28.14 $42,210.00
Disclosure

SEC source: 0001666071-19-000066 · wf-form4_156322823672024.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,127

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018

Read SEC document
June 17, 2019 Filed Jun 19, 2019 20:38 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,500 $25.18 $37,770.00
Disclosure

SEC source: 0001209191-19-038039 · doc4.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,627

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $24.96 to $25.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
May 15, 2019 Filed May 17, 2019 22:00 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,500 $19.99 $29,985.00
Disclosure

SEC source: 0001209191-19-031090 · doc4.xml · nonDerivative · entry 1

Evans David Thomas · CIK 0001730451 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,127

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 963 shares of the Common Stock acquired under the Issuer's Employee Stock Purchase Plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.